ClinicalTrials.gg
CompletedNCT04998604EVERESTUpdated Oct 23, 2025Results posted

EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients

A Phase 4 interventional study of Dupilumab and Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma, sponsored by Sanofi. Completed at 87 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-23.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing dupilumab in Asthma — 7 open to participants now, 12 under way, 2 of them phase 3. dupilumab · Asthma.

Enrollment
9th of 31
360 · median 120
Started
2021
with 2 others
Phase 4
14 of 31
5 open now
Registered
20th of 31
by date
Lead sponsor
15 of 31
Sanofi

Among the 31 studies testing dupilumab in Asthma, this one is the 9th largest by enrollment, is one of 3 that started in 2021, is one of 14 in phase 4, and was the 20th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 31 studies testing dupilumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing dupilumab in Asthma, or all of them as a file.
02

Study summary

Primary Objective

-To evaluate the efficacy of dupilumab compared to omalizumab in reducing the polyp size and improving sense of smell

Secondary Objectives

  • To evaluate the efficacy of dupilumab in improving chronic rhinosinusitis with nasal polyps (CRSwNP) symptoms at Week 24 compared to omalizumab
  • To evaluate the efficacy of dupilumab in improving CRSwNP total symptom score (TSS) at Week 24 compared to omalizumab
  • To evaluate the effect of dupilumab on health related quality of life (HRQoL) at week 24 compared to omalizumab
  • To evaluate the efficacy of dupilumab in improving nasal peak inspiratory flow at Week 24 compared to omalizumab
  • To evaluate the effect of dupilumab on CRSwNP overall disease severity at Week 24 compared to omalizumab
  • To evaluate the safety of dupilumab and omalizumab
Read the detailed description

Study duration per participant will be 38 weeks. The study will comprise 3 periods: 28 days ± 3 days screening and run-in period; 24 weeks Randomized investigational medicinal product (IMP) intervention period; up to 12 weeks follow-up period.

03

Conditions studied

  • Chronic Rhinosinusitis With Nasal Polyps
  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be at least 18 (or the legal age of consent in the jurisdiction in which the study is taking place) years of age inclusive, at the time of signing the .
  • Participants with bilateral sino-nasal polyposis, that despite prior treatment with Systemic (SCS) anytime within the past 2 years; and/or medical /intolerance to SCS; and/or prior surgery for NP have:

    • An endoscopic bilateral NPS of at least 5 out of a maximum score of 8 (with a minimum score of 2 in each nasal cavity) at visit 1; AND
    • Ongoing symptoms of Nasal congestion/blockade/obstruction and loss of smell for at least 8 weeks before screening (Visit 1), AND
    • Nasal congestion/blockade/obstruction and a weekly average severity greater than 1 in the 7 days before randomization (Visit 2) AND
    • loss of smell symptom severity score 2 or 3 at screening (Visit 1) and a weekly average severity of greater than 1 in the 7 days before randomization (Visit 2).
  • Participants with a physician diagnosis of asthma based on the Global Initiative for Asthma (GINA) 2020 treated with low, medium or high dose inhaled corticosteroids (ICS) and a second controller (ie, LABA), a third controller is allowed but not mandatory. The dose regimen was to be stable for at least 1 month before Visit 1 (screening visit) and during the screening and run-in period.
  • Asthma Control Questionnaire 5-question version (ACQ-5) score ≥1.5 at Visits 1 or 2.
  • Treatment with intranasal mometasone ≥200 μg once daily (QD) (or equivalent of another INCS) for 1 month prior to Visit 1 and during the run-in period (for CRSwNP).
  • Eligibility as per omalizumab drug-dosing table (serum IgE level ≥30 to ≤1500 IU/mL and body weight ≥30 to ≤150 kg) and ability to be dosed per the dosing table.

Exclusion criteria

Exclusion Criteria:

Participants were excluded from the study if any of the following criteria apply:

  • Participants who underwent any sinus intranasal surgery (including polypectomy) within 6 months before Visit 1.
  • Participants who had a sino-nasal surgery changing the lateral wall structure of the nose, making impossible the evaluation of NPS.
  • Participants with conditions/concomitant diseases making them non evaluable at Visit 1 or for the primary efficacy endpoint such as: Antrochoanal polyps, Nasal septal deviation that would occlude at least one nostril, Acute sinusitis, nasal infection, or upper respiratory infection.
  • Severe asthma exacerbation requiring treatment with SCS in the last 4 weeks prior to Visit 1 and during screening.
  • Severe concomitant illness(es) that, in the Investigator's judgment, would adversely affect the participant's participation in the study
  • Diagnosed with, suspected of, or at high risk of endoparasitic infection, and/or use of antiparasitic drugs within 2 weeks before Visit 1 (screening visit) or during the screening and run-in period.
  • History of (HIV) infection or positive HIV 1/2 serology at Visit 1 (screening visit).
  • Known or suspected immunodeficiency, including history of invasive opportunistic infections
  • Active or history of malignancy within 5 years before Visit 1 (screening visit), except completely treated in situ carcinoma of the cervix and completely treated and resolved non squamous or basal cell carcinoma of the skin.
  • History of systemic or anaphylaxis to dupilumab and omalizumab, including any
  • Treatment with a live (attenuated) vaccine within 4 weeks before Visit 1 (screening visit).

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
360 participants (actual)

Study arms

  • Experimental
    Dupilumab 300 mg Q2W

    Participants received dupilumab 300 milligrams (mg) subcutaneous (SC) injection every 2 weeks (Q2W) for 24 weeks.

    Drug: Dupilumab · Drug: Placebo

  • Experimental
    Omalizumab 75 to 600 mg Q2W/Q4W

    Participants received omalizumab 75 to 600 mg SC injection Q2W/every 4 weeks (Q4W) based on their serum immunoglobulin E (IgE) levels and body weight for 24 weeks.

    Drug: Omalizumab · Drug: Placebo

Interventions

  • solution for injection subcutaneous

    Also known as: SAR231893 Dupixent

  • solution for injection subcutaneous

    Also known as: Xolair

  • DrugPlacebo

    solution for injection subcutaneous

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 24 in Nasal Polyp Score

    The NPS was assessed by the independent physician to grade the extent/severity of nasal polyps based on evaluation by nasal endoscopy. The NPS scores for each nostril was graded based on polyp size from 0 (no polyps) to 4 (large polyps causing complete obstruction of the inferior nasal cavity). The total NPS score was calculated as the sum of right and left nostril scores and ranged from 0 (no polyps) to 8 (large polyps). Higher scores indicated more extensive or severe nasal polyps. Negative change from baseline indicated less severity of nasal polyps. Baseline was defined as the last available valid (non-missing) value up to and including the day of first administration of study treatment.

    Time frame: Baseline (Day 1) and Week 24

  2. Change From Baseline to Week 24 in University of Pennsylvania Smell Identification Test

    The UPSIT was a 40-item test to quantitatively assess human olfactory function. The UPSIT test consisted of 4 booklets, each containing 10 odorants with 1 odorant per page. The participant was asked to release the odorant by rubbing the brown-strip (contained odorant microcapsules) with the tip of a pencil and to indicate which of 4 words best described the odor. Thus, each participant received a score out of 40 possible correct answers. The total UPSIT score ranged from 0 (loss of smell/anosmia) to 40 (normal sense of smell/normosmia). Higher scores indicated better olfactory function. Positive change from baseline indicated normal olfactory function. Baseline was defined as the last available valid (non-missing) value up to and including the day of first administration of study treatment.

    Time frame: Baseline (Day 1) and Week 24

Secondary outcomes

  1. Change From Baseline to Week 24 in the Loss of Smell Score of the Chronic Rhinosinusitis With Nasal Polyp (CRSwNP) Nasal Symptom Diary

    The nasal symptom diary was designed to assess the severity of chronic rhinosinusitis nasal symptoms daily. These symptoms included nasal congestion (NC)/obstruction, loss of smell, anterior rhinorrhea, and posterior rhinorrhea. The severity of loss of smell was scored by participants using a scale ranged from 0 to 3 (where, 0= no symptoms, 1= mild symptoms, 2= moderate symptoms and 3= severe symptoms that were hard to tolerate, caused interference with activities, or daily living). Higher scores indicated greater symptom severity. Negative change from baseline indicated less severe symptom. Baseline value was calculated by averaging the data collected/recorded from Day -6 to Day 1.

    Time frame: Baseline (average of Day -6 to Day 1) and Week 24

  2. Change From Baseline to Week 24 in the Nasal Congestion Score of the Chronic Rhinosinusitis With Nasal Polyp Nasal Symptom Diary

    The nasal symptom diary was designed to assess the severity of chronic rhinosinusitis nasal symptoms daily. These symptoms included NC/obstruction, loss of smell, anterior rhinorrhea, and posterior rhinorrhea. The severity of NC was scored by participants using a scale ranged from 0 to 3 (where, 0= no symptoms, 1= mild symptoms, 2= moderate symptoms and 3= severe symptoms that were hard to tolerate, caused interference with activities, or daily living). Higher scores indicated greater symptom severity. Negative change from baseline indicated less severe symptom. Baseline value was calculated by averaging the data collected/recorded from Day -6 to Day 1.

    Time frame: Baseline (average of Day -6 to Day 1) and Week 24

  3. Change From Baseline to Week 24 in Total Symptom Score (TSS) Derived From the Chronic Rhinosinusitis With Nasal Polyp Nasal Symptom Diary

    The TSS is a composite score consisted of the following symptoms assessed daily in the morning: NC/obstruction, decreased/loss of sense of smell, and rhinorrhea (average of anterior/posterior nasal discharge). Each item was scored on a scale ranged from 0 to 3 (where, 0= no symptoms, 1= mild symptoms, 2= moderate symptoms and 3= severe symptoms that were hard to tolerate, and caused interference with activities, or daily living). Higher score indicated greater symptom severity. The TSS score was calculated by summing the individual symptom score and ranged from 0 (no symptoms) to 9 (severe symptoms). Higher scores on the TSS indicated greater symptom severity. Negative change from baseline indicated less severe symptom. Baseline was calculated by averaging the data collected/recorded from Day -6 to Day 1.

    Time frame: Baseline (average of Day -6 to Day 1) and Week 24

  4. Change From Baseline to Week 24 in Sino-Nasal Outcome Test 22-Items (SNOT-22) Total Score

    The SNOT-22 is a patient-reported outcome questionnaire designed to assess the impact of chronic rhinosinusitis on participants' health-related quality of life. The SNOT-22 consisted of 22 items covering symptoms, social/emotional impact, productivity, and sleep consequences of chronic rhinosinusitis. Each item was rated on a 6-point Likert scale response option, score ranged from 0 (no problem) to 5 (problem as bad as it can be). The SNOT-22 total score was the sum of each item score, and it ranged from 0 (no problem) to 110 (problem as bad as it can be). Higher scores indicated greater rhinosinusitis-related health burden, meaning for this parameter lower score indicated better condition. Negative change from baseline indicated improvement in health-related quality of life. Baseline was defined as the last available valid (non-missing) value up to and including the day of first administration of study treatment.

    Time frame: Baseline (Day 1) and Week 24

  5. Change From Baseline to Week 24 in Sino-Nasal Outcome Test 22-Items: Nasal Domain Score

    SNOT-22 is a patient-reported outcome questionnaire designed to assess impact of chronic rhinosinusitis on participants' health-related quality of life. SNOT-22 was categorized into 5 domains: Nasal (items 1, 2, 3, 4, 5, 6, 7 and 12); Ear/Facial (items 8, 9, 10 and 11); Sleep (items 13, 14, 15 and 16); Function (items 17, 18 and 19); Emotion (items 20, 21 and 22). Each item of Nasal domain was rated on a 6-point Likert scale ranged from 0 (no problem) to 5 (problem as bad as it can be) with higher score indicated greater rhinosinusitis-related health burden. Total score of Nasal domain was average score of items of nasal domain, and ranged from 0 (no problem) to 5 (problem as bad as it can be), where higher score indicated greater rhinosinusitis-related health burden. Negative change from baseline indicated improvement in health-related quality of life. Baseline was defined as last available valid (non-missing) value up to and including day of first administration of study treatment.

    Time frame: Baseline (Day 1) and Week 24

  6. Change From Baseline to Week 24 in Nasal Peak Inspiratory Flow (NPIF)

    The NPIF evaluation represented a physiologic measure of the air flow through both nasal cavities during forced inspiration. The NPIF is the best validated technique for the evaluation of nasal flow through the nose. Participants were issued an NPIF meter and were instructed on the use of the device and written instructions on the use of the NPIF meter was provided. Higher NPIF values were indicative of better nasal air flow. Positive change from baseline indicated better nasal air flow. Baseline was the mean measurement recorded for the 7 days (Day -6 to Day 1) prior to first dose of study treatment.

    Time frame: Baseline (average of Day -6 to Day 1) and Week 24

  7. Change From Baseline to Week 24 in Rhinosinusitis Visual Analogue Scale (Rhinosinusitis VAS)

    The rhinosinusitis severity VAS was used to evaluate the overall severity of the rhinosinusitis. It is a recommended scale to determine the participant's disease severity and to guide the treatment for chronic rhinosinusitis. The participants were asked to answer the following question: "How troublesome are your symptoms of your rhinosinusitis" on a 10-centimeter VAS from 0 (not troublesome) to 10 (worst thinkable troublesome). Higher scores on the VAS score indicated more severe chronic rhinosinusitis. Negative change from baseline indicated less severity of rhinosinusitis. Baseline was defined as the last available valid (non-missing) value up to and including the day of first administration of study treatment.

    Time frame: Baseline (Day 1) and Week 24

  8. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs) and Treatment-Emergent Adverse Events of Special Interest (AESIs)

    An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE was defined as any AE that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required. The TEAEs was defined as an AEs that occurred from the first administration of the study treatment (on Day 1) up to 98 days after the last dose of study treatment administration.

    Time frame: From first dose of study treatment administration (Day 1) up to 98 days after the last dose of study treatment administration (considering the maximum duration of treatment exposure) i.e., up to approximately 329 days

07

Results

Posted Oct 23, 2025

Participant flow

The study was conducted at 87 active centers in 17 countries. A total of 819 participants were screened between 27 September 2021 and 25 April 2024, of which 459 participants were screen failures. Screen failures were mainly due to not meeting eligibility criteria.

Participant flow — Overall Study
MilestoneDupilumab 300 mg Q2WOmalizumab 75 to 600 mg Q2W/Q4W
Started181179
Randomized and treated179173
Completed174165
Not completed714
Withdrew: Adverse event32
Withdrew: Withdrawal by subject24
Withdrew: Not related to coronavirus disease 2019 pandemic28

Outcome measures

PrimaryChange From Baseline to Week 24 in Nasal Polyp Score

The NPS was assessed by the independent physician to grade the extent/severity of nasal polyps based on evaluation by nasal endoscopy. The NPS scores for each nostril was graded based on polyp size from 0 (no polyps) to 4 (large polyps causing complete obstruction of the inferior nasal cavity). The total NPS score was calculated as the sum of right and left nostril scores and ranged from 0 (no polyps) to 8 (large polyps). Higher scores indicated more extensive or severe nasal polyps. Negative change from baseline indicated less severity of nasal polyps. Baseline was defined as the last available valid (non-missing) value up to and including the day of first administration of study treatment.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 24 in Nasal Polyp Score
score on a scaleDupilumab 300 mg Q2WOmalizumab 75 to 600 mg Q2W/Q4W
Change From Baseline to Week 24 in Nasal Polyp Score-2.65 (-2.95 to -2.36)-1.05 (-1.35 to -0.75)
Statistical analysis
  • Dupilumab 300 mg Q2W vs Omalizumab 75 to 600 mg Q2W/Q4W · ANCOVA · p = <0.001 (The threshold for statistical significance was 0.05 level.) · Least squares (ls) mean difference: -1.60 · 95% CI -1.96 to -1.25
PrimaryChange From Baseline to Week 24 in University of Pennsylvania Smell Identification Test

The UPSIT was a 40-item test to quantitatively assess human olfactory function. The UPSIT test consisted of 4 booklets, each containing 10 odorants with 1 odorant per page. The participant was asked to release the odorant by rubbing the brown-strip (contained odorant microcapsules) with the tip of a pencil and to indicate which of 4 words best described the odor. Thus, each participant received a score out of 40 possible correct answers. The total UPSIT score ranged from 0 (loss of smell/anosmia) to 40 (normal sense of smell/normosmia). Higher scores indicated better olfactory function. Positive change from baseline indicated normal olfactory function. Baseline was defined as the last available valid (non-missing) value up to and including the day of first administration of study treatment.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 24 in University of Pennsylvania Smell Identification Test
score on a scaleDupilumab 300 mg Q2WOmalizumab 75 to 600 mg Q2W/Q4W
Change From Baseline to Week 24 in University of Pennsylvania Smell Identification Test12.7 (11.3 to 14.1)4.7 (3.2 to 6.1)
Statistical analysis
  • Dupilumab 300 mg Q2W vs Omalizumab 75 to 600 mg Q2W/Q4W · ANCOVA · p = <0.001 (The threshold for statistical significance was 0.05 level.) · Ls mean difference: 8.0 · 95% CI 6.3 to 9.7
SecondaryChange From Baseline to Week 24 in the Loss of Smell Score of the Chronic Rhinosinusitis With Nasal Polyp (CRSwNP) Nasal Symptom Diary

The nasal symptom diary was designed to assess the severity of chronic rhinosinusitis nasal symptoms daily. These symptoms included nasal congestion (NC)/obstruction, loss of smell, anterior rhinorrhea, and posterior rhinorrhea. The severity of loss of smell was scored by participants using a scale ranged from 0 to 3 (where, 0= no symptoms, 1= mild symptoms, 2= moderate symptoms and 3= severe symptoms that were hard to tolerate, caused interference with activities, or daily living). Higher scores indicated greater symptom severity. Negative change from baseline indicated less severe symptom. Baseline value was calculated by averaging the data collected/recorded from Day -6 to Day 1.

Time frame:
Baseline (average of Day -6 to Day 1) and Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 24 in the Loss of Smell Score of the Chronic Rhinosinusitis With Nasal Polyp (CRSwNP) Nasal Symptom Diary
score on a scaleDupilumab 300 mg Q2WOmalizumab 75 to 600 mg Q2W/Q4W
Change From Baseline to Week 24 in the Loss of Smell Score of the Chronic Rhinosinusitis With Nasal Polyp (CRSwNP) Nasal Symptom Diary-1.55 (-1.71 to -1.38)-0.74 (-0.90 to -0.57)
Statistical analysis
  • Dupilumab 300 mg Q2W vs Omalizumab 75 to 600 mg Q2W/Q4W · ANCOVA · p = <0.001 (The threshold for statistical significance was 0.05 level.) · Ls mean difference: -0.81 · 95% CI -1.01 to -0.61
SecondaryChange From Baseline to Week 24 in the Nasal Congestion Score of the Chronic Rhinosinusitis With Nasal Polyp Nasal Symptom Diary

The nasal symptom diary was designed to assess the severity of chronic rhinosinusitis nasal symptoms daily. These symptoms included NC/obstruction, loss of smell, anterior rhinorrhea, and posterior rhinorrhea. The severity of NC was scored by participants using a scale ranged from 0 to 3 (where, 0= no symptoms, 1= mild symptoms, 2= moderate symptoms and 3= severe symptoms that were hard to tolerate, caused interference with activities, or daily living). Higher scores indicated greater symptom severity. Negative change from baseline indicated less severe symptom. Baseline value was calculated by averaging the data collected/recorded from Day -6 to Day 1.

Time frame:
Baseline (average of Day -6 to Day 1) and Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 24 in the Nasal Congestion Score of the Chronic Rhinosinusitis With Nasal Polyp Nasal Symptom Diary
score on a scaleDupilumab 300 mg Q2WOmalizumab 75 to 600 mg Q2W/Q4W
Change From Baseline to Week 24 in the Nasal Congestion Score of the Chronic Rhinosinusitis With Nasal Polyp Nasal Symptom Diary-1.63 (-1.76 to -1.49)-1.05 (-1.18 to -0.91)
Statistical analysis
  • Dupilumab 300 mg Q2W vs Omalizumab 75 to 600 mg Q2W/Q4W · ANCOVA · p = <0.001 (The threshold for statistical significance was 0.05 level.) · Ls mean difference: -0.58 · 95% CI -0.74 to -0.42
SecondaryChange From Baseline to Week 24 in Total Symptom Score (TSS) Derived From the Chronic Rhinosinusitis With Nasal Polyp Nasal Symptom Diary

The TSS is a composite score consisted of the following symptoms assessed daily in the morning: NC/obstruction, decreased/loss of sense of smell, and rhinorrhea (average of anterior/posterior nasal discharge). Each item was scored on a scale ranged from 0 to 3 (where, 0= no symptoms, 1= mild symptoms, 2= moderate symptoms and 3= severe symptoms that were hard to tolerate, and caused interference with activities, or daily living). Higher score indicated greater symptom severity. The TSS score was calculated by summing the individual symptom score and ranged from 0 (no symptoms) to 9 (severe symptoms). Higher scores on the TSS indicated greater symptom severity. Negative change from baseline indicated less severe symptom. Baseline was calculated by averaging the data collected/recorded from Day -6 to Day 1.

Time frame:
Baseline (average of Day -6 to Day 1) and Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 24 in Total Symptom Score (TSS) Derived From the Chronic Rhinosinusitis With Nasal Polyp Nasal Symptom Diary
score on a scaleDupilumab 300 mg Q2WOmalizumab 75 to 600 mg Q2W/Q4W
Change From Baseline to Week 24 in Total Symptom Score (TSS) Derived From the Chronic Rhinosinusitis With Nasal Polyp Nasal Symptom Diary-4.48 (-4.82 to -4.14)-2.73 (-3.09 to -2.38)
Statistical analysis
  • Dupilumab 300 mg Q2W vs Omalizumab 75 to 600 mg Q2W/Q4W · ANCOVA · p = <0.001 (The threshold for statistical significance was 0.05 level.) · Ls mean difference: -1.74 · 95% CI -2.15 to -1.33
SecondaryChange From Baseline to Week 24 in Sino-Nasal Outcome Test 22-Items (SNOT-22) Total Score

The SNOT-22 is a patient-reported outcome questionnaire designed to assess the impact of chronic rhinosinusitis on participants' health-related quality of life. The SNOT-22 consisted of 22 items covering symptoms, social/emotional impact, productivity, and sleep consequences of chronic rhinosinusitis. Each item was rated on a 6-point Likert scale response option, score ranged from 0 (no problem) to 5 (problem as bad as it can be). The SNOT-22 total score was the sum of each item score, and it ranged from 0 (no problem) to 110 (problem as bad as it can be). Higher scores indicated greater rhinosinusitis-related health burden, meaning for this parameter lower score indicated better condition. Negative change from baseline indicated improvement in health-related quality of life. Baseline was defined as the last available valid (non-missing) value up to and including the day of first administration of study treatment.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 24 in Sino-Nasal Outcome Test 22-Items (SNOT-22) Total Score
score on a scaleDupilumab 300 mg Q2WOmalizumab 75 to 600 mg Q2W/Q4W
Change From Baseline to Week 24 in Sino-Nasal Outcome Test 22-Items (SNOT-22) Total Score-44.6 (-47.9 to -41.3)-31.9 (-35.2 to -28.5)
SecondaryChange From Baseline to Week 24 in Sino-Nasal Outcome Test 22-Items: Nasal Domain Score

SNOT-22 is a patient-reported outcome questionnaire designed to assess impact of chronic rhinosinusitis on participants' health-related quality of life. SNOT-22 was categorized into 5 domains: Nasal (items 1, 2, 3, 4, 5, 6, 7 and 12); Ear/Facial (items 8, 9, 10 and 11); Sleep (items 13, 14, 15 and 16); Function (items 17, 18 and 19); Emotion (items 20, 21 and 22). Each item of Nasal domain was rated on a 6-point Likert scale ranged from 0 (no problem) to 5 (problem as bad as it can be) with higher score indicated greater rhinosinusitis-related health burden. Total score of Nasal domain was average score of items of nasal domain, and ranged from 0 (no problem) to 5 (problem as bad as it can be), where higher score indicated greater rhinosinusitis-related health burden. Negative change from baseline indicated improvement in health-related quality of life. Baseline was defined as last available valid (non-missing) value up to and including day of first administration of study treatment.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 24 in Sino-Nasal Outcome Test 22-Items: Nasal Domain Score
score on a scaleDupilumab 300 mg Q2WOmalizumab 75 to 600 mg Q2W/Q4W
Change From Baseline to Week 24 in Sino-Nasal Outcome Test 22-Items: Nasal Domain Score-2.4 (-2.6 to -2.2)-1.6 (-1.8 to -1.4)
SecondaryChange From Baseline to Week 24 in Nasal Peak Inspiratory Flow (NPIF)

The NPIF evaluation represented a physiologic measure of the air flow through both nasal cavities during forced inspiration. The NPIF is the best validated technique for the evaluation of nasal flow through the nose. Participants were issued an NPIF meter and were instructed on the use of the device and written instructions on the use of the NPIF meter was provided. Higher NPIF values were indicative of better nasal air flow. Positive change from baseline indicated better nasal air flow. Baseline was the mean measurement recorded for the 7 days (Day -6 to Day 1) prior to first dose of study treatment.

Time frame:
Baseline (average of Day -6 to Day 1) and Week 24
Reported as:
Least squares mean · Liters per minute
Change From Baseline to Week 24 in Nasal Peak Inspiratory Flow (NPIF)
Liters per minuteDupilumab 300 mg Q2WOmalizumab 75 to 600 mg Q2W/Q4W
Change From Baseline to Week 24 in Nasal Peak Inspiratory Flow (NPIF)68.96 (60.90 to 77.02)37.69 (29.28 to 46.09)
SecondaryChange From Baseline to Week 24 in Rhinosinusitis Visual Analogue Scale (Rhinosinusitis VAS)

The rhinosinusitis severity VAS was used to evaluate the overall severity of the rhinosinusitis. It is a recommended scale to determine the participant's disease severity and to guide the treatment for chronic rhinosinusitis. The participants were asked to answer the following question: "How troublesome are your symptoms of your rhinosinusitis" on a 10-centimeter VAS from 0 (not troublesome) to 10 (worst thinkable troublesome). Higher scores on the VAS score indicated more severe chronic rhinosinusitis. Negative change from baseline indicated less severity of rhinosinusitis. Baseline was defined as the last available valid (non-missing) value up to and including the day of first administration of study treatment.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 24 in Rhinosinusitis Visual Analogue Scale (Rhinosinusitis VAS)
units on a scaleDupilumab 300 mg Q2WOmalizumab 75 to 600 mg Q2W/Q4W
Change From Baseline to Week 24 in Rhinosinusitis Visual Analogue Scale (Rhinosinusitis VAS)-5.43 (-5.96 to -4.90)-3.56 (-4.11 to -3.01)
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs) and Treatment-Emergent Adverse Events of Special Interest (AESIs)

An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE was defined as any AE that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required. The TEAEs was defined as an AEs that occurred from the first administration of the study treatment (on Day 1) up to 98 days after the last dose of study treatment administration.

Time frame:
From first dose of study treatment administration (Day 1) up to 98 days after the last dose of study treatment administration (considering the maximum duration of treatment exposure) i.e., up to approximately 329 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs) and Treatment-Emergent Adverse Events of Special Interest (AESIs)
ParticipantsDupilumab 300 mg Q2WOmalizumab 75 to 600 mg Q2W/Q4W
Any TEAE115116
Any Serious TEAE37
Any Treatment-Emergent AESI42

Adverse events

Collected over Serious adverse events (AEs) and other AEs were collected from first dose of study treatment administration (Day 1) up to 98 days after the last dose of study treatment administration (considering the maximum duration of treatment exposure) i.e., up to approximately 329 days. All-cause mortality (deaths) were collected from first dose of study treatment (Day 1) up to end of follow-up for death for each participant, i.e., up to approximately 39 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dupilumab 300 mg Q2W0/179 (0%)3/179 (1.7%)48/179 (26.8%)
Omalizumab 75 to 600 mg Q2W/Q4W0/173 (0%)7/173 (4%)53/173 (30.6%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventDupilumab 300 mg Q2WOmalizumab 75 to 600 mg Q2W/Q4W
PneumoniaInfections and infestations0/1792/173
Atrial FibrillationCardiac disorders0/1791/173
Eosinophilic Granulomatosis With PolyangiitisImmune system disorders0/1791/173
AppendicitisInfections and infestations0/1791/173
NeuroborreliosisInfections and infestations0/1791/173
ContusionInjury, poisoning and procedural complications0/1791/173
Pancreatitis AcuteGastrointestinal disorders1/1790/173
Mycobacterium Avium Complex InfectionInfections and infestations1/1790/173
Pneumonia KlebsiellaInfections and infestations1/1790/173
PregnancyPregnancy, puerperium and perinatal conditions1/1790/173
Most frequent other events
Most frequent other events
EventDupilumab 300 mg Q2WOmalizumab 75 to 600 mg Q2W/Q4W
Accidental OverdoseInjury, poisoning and procedural complications12/17921/173
NasopharyngitisInfections and infestations21/17920/173
HeadacheNervous system disorders10/17913/173
Upper Respiratory Tract InfectionInfections and infestations10/1798/173

Baseline characteristics

The intent-to-treat (ITT) analysis set included all randomized participants.

Age, Continuous
Age, Continuous(years)Dupilumab 300 mg Q2WOmalizumab 75 to 600 mg Q2W/Q4WTotal
Mean51.0 ± 13.3352.1 ± 12.9051.5 ± 13.11
Sex: Female, Male
Sex: Female, Male(Participants)Dupilumab 300 mg Q2WOmalizumab 75 to 600 mg Q2W/Q4WTotal
Female7488162
Male10791198
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dupilumab 300 mg Q2WOmalizumab 75 to 600 mg Q2W/Q4WTotal
American Indian or Alaska Native022
Asian112
Black or African American213
White171170341
Multiple011
Not Reported628
Unknown123
Nasal Polyp Score (NPS)
Nasal Polyp Score (NPS)(score on a scale)Dupilumab 300 mg Q2WOmalizumab 75 to 600 mg Q2W/Q4WTotal
Mean6.11 ± 1.1656.15 ± 1.2776.13 ± 1.220
University of Pennsylvania Smell Identification Test (UPSIT)
University of Pennsylvania Smell Identification Test (UPSIT)(score on a scale)Dupilumab 300 mg Q2WOmalizumab 75 to 600 mg Q2W/Q4WTotal
Mean11.1 ± 5.4511.0 ± 6.1311.1 ± 5.79
08

Study locations

87 sites
  • Cedars Sinai Medical Center Site Number : 8400026
    Los Angeles, California 90048, United States
  • Asthma Allergy & Immunology Clinical Research Unit Site Number : 8400027
    Tampa, Florida 33613, United States
  • Northwestern University Site Number : 8400001
    Chicago, Illinois 60611, United States
  • University of Illinois
    Chicago, Illinois 60612, United States
  • Advanced ENT and Allergy Site Number : 8400013
    Louisville, Kentucky 40220, United States
  • University of Missouri Health Care - University Hospital Site Number : 8400016
    Columbia, Missouri 65212, United States
  • Northwell Health Site Number : 8400044
    Great Neck, New York 11021, United States
  • University of Rochester Site Number : 8400015
    Rochester, New York 14642, United States
  • Cleveland Clinic Foundation Site Number : 8400029
    Cleveland, Ohio 44195, United States
  • Optimed Research, LTD Site Number : 8400014
    Columbus, Ohio 43235, United States
  • Allergy, Asthma and Clinical Research Center Site Number : 8400037
    Oklahoma City, Oklahoma 73120, United States
  • Essential Medical Research, LLC Site Number : 8400024
    Tulsa, Oklahoma 74137, United States
  • Oregon Health & Science University Site Number : 8400031
    Portland, Oregon 97239, United States
  • University of Texas Health Science Center- Site Number : 8400019
    Houston, Texas 77030, United States
  • Chryaslis Clinical Research Site Number : 8400017
    St. George, Utah 84790, United States
  • Eastern Virginia Medical School Site Number : 8400010
    Norfolk, Virginia 23507, United States
  • Investigational Site Number : 0560001
    Ghent, 9000, Belgium
  • Investigational Site Number : 0560002
    Leuven, 3000, Belgium
  • Investigational Site Number : 0560003
    Woluwe-Saint-Lambert, 1200, Belgium
  • Investigational Site Number : 1240004
    London, Ontario N6A 5A5, Canada
  • Investigational Site Number : 1240002
    Montreal, Quebec H4A 3J1, Canada
  • Investigational Site Number : 1240003
    Québec, G1V 4G5, Canada
  • Investigational Site Number : 2030007
    Benešov, 256 01, Czechia
  • Investigational Site Number : 2030001
    Hradec Králové, 50005, Czechia
  • Investigational Site Number : 2030003
    Ostrava - Poruba, 70852, Czechia
  • Investigational Site Number : 2030002
    Pardubice, 53203, Czechia
  • Investigational Site Number : 2030012
    Pilsen, 30599, Czechia
  • Investigational Site Number : 2030010
    Prague, 10034, Czechia
  • Investigational Site Number : 2030006
    Prague, 12808, Czechia
  • Investigational Site Number : 2030008
    Prague, 14059, Czechia
  • Investigational Site Number : 2030004
    Praha 5 - Motole, 15006, Czechia
  • Investigational Site Number : 2080003
    Aarhus, 8200, Denmark
  • Investigational Site Number : 2080001
    Copenhagen, 2100, Denmark
  • Investigational Site Number : 2460003
    Helsinki, 00029 HUS, Finland
  • Investigational Site Number : 2460002
    Tampere, 33520, Finland
  • Investigational Site Number : 2500009
    Créteil, 94010, France
  • Investigational Site Number : 2500006
    La Roche-sur-Yon, 85925, France
  • Investigational Site Number : 2500008
    Le Kremlin-Bicêtre, 94275, France
  • Investigational Site Number : 2500002
    Lille, 59037, France
  • Investigational Site Number : 2500004
    Marseille, 13005, France
  • Investigational Site Number : 2500005
    Montpellier, 34295, France
  • Investigational Site Number : 2500007
    Toulouse, 31059, France
  • Investigational Site Number : 2760002
    Berlin, 13353, Germany
  • Investigational Site Number : 2760004
    Düsseldorf, 40225, Germany
  • Investigational Site Number : 2760003
    München, 81377, Germany
  • Investigational Site Number : 2760001
    Münster, 48149, Germany
  • Investigational Site Number : 3480007
    Budapest, 1083, Hungary
  • Investigational Site Number : 3480004
    Budapest, 1115, Hungary
  • Investigational Site Number : 3480005
    Debrecen, 4026, Hungary
  • Investigational Site Number : 3480006
    Edelény, 3780, Hungary
  • Investigational Site Number : 3480002
    Pécs, 7621, Hungary
  • Investigational Site Number : 3480001
    Szeged, 6725, Hungary
  • Investigational Site Number : 3800002
    Rome, Lazio 00168, Italy
  • Investigational Site Number : 3800001
    Rozzano, Lombardy 20089, Italy
  • Investigational Site Number : 3800003
    Catania, 95123, Italy
  • Investigational Site Number : 3800004
    Florence, 50134, Italy
  • Investigational Site Number : 3800006
    Milan, 20132, Italy
  • Investigational Site Number : 3800005
    Varese, 21100, Italy
  • Investigational Site Number : 4840003
    Guadalajara, Jalisco 44100, Mexico
  • Investigational Site Number : 4840002
    Chihuahua City, 31000, Mexico
  • Investigational Site Number : 4840004
    Durango, 34000, Mexico
  • Investigational Site Number : 6160004
    Poznan, Greater Poland Voivodeship 60-693, Poland
  • Investigational Site Number : 6160008
    Warsaw, Masovian Voivodeship 04-141, Poland
  • Investigational Site Number : 6160005
    Katowice, Silesian Voivodeship 40-611, Poland
  • Investigational Site Number : 6160001
    Krakow, 30-033, Poland
  • Investigational Site Number : 6160007
    Lodz, 90141, Poland
  • Investigational Site Number : 6160006
    Środa Wielkopolska, 63000, Poland
  • Investigational Site Number : 6200005
    Almada, 2801-951, Portugal
  • Investigational Site Number : 6200003
    Aveiro, 3814-501, Portugal
  • Investigational Site Number : 6200006
    Guimarães, 4810-061, Portugal
  • Investigational Site Number : 6200001
    Matosinhos Municipality, 4454-509, Portugal
  • Investigational Site Number : 6200007
    Santa Maria da Feira, 4520-211, Portugal
  • Investigational Site Number : 6420002
    Brasov, 500283, Romania
  • Investigational Site Number : 6420004
    Craiova, 200222, Romania
  • Investigational Site Number : 7240001
    Seville, Andalusia 41009, Spain
  • Investigational Site Number : 7240005
    Barcelona, Barcelona [Barcelona] 08036, Spain
  • Investigational Site Number : 7240008
    L'Hospitalet de Llobregat, Barcelona [Barcelona] 08907, Spain
  • Investigational Site Number : 7240003
    Jerez de la Frontera, Cádiz 11407, Spain
  • Investigational Site Number : 7240007
    Majadahonda, Madrid 28222, Spain
  • Investigational Site Number : 7240004
    Madrid / Madrid, Madrid, Comunidad de 28040, Spain
  • Investigational Site Number : 7240006
    Pamplona, Navarre 31080, Spain
  • Investigational Site Number : 7520003
    Gothenburg, 413 45, Sweden
  • Investigational Site Number : 7520002
    Lund, 221 85, Sweden
  • Investigational Site Number : 7520001
    Stockholm, 171 76, Sweden
  • Investigational Site Number : 8260003
    Wigan, Lancashire WN6 9EP, United Kingdom
  • Investigational Site Number : 8260002
    Manchester, M23 9LT, United Kingdom
  • Investigational Site Number : 8260001
    Newcastle upon Tyne, NE7 7DN, United Kingdom
09

References and documents

Publications

  • De Corso E, Canonica GW, Heffler E, Springer M, Grzegorzek T, Viana M, Horvath Z, Mullol J, Gevaert P, Michel J, Peters AT, Wagenmann M, Zaghloul S, Zhang M, Corbett M, Nash S, Angello JT, Radwan A, Deniz Y, Martin A, Hellings PW. Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial. Lancet Respir Med. 2025 Dec;13(12):1067-1077. doi: 10.1016/S2213-2600(25)00287-5. Epub 2025 Sep 28. PubMed 41033334 ↗
  • De Prado Gomez PharmD MSc L, Khan Mbbs Mph AH, Peters Md AT, Bachert Md PhD C, Wagenmann Md M, Heffler Md PhD E, Hopkins BMBCh C, Hellings Md PhD PW, Zhang PhD M, Xing PhD J, Rowe Md P, Jacob-Nara Md Mph DHSc JA. Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design. Am J Rhinol Allergy. 2022 Nov;36(6):788-795. doi: 10.1177/19458924221112211. Epub 2022 Jul 15. PubMed 35837739 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Oct 2024, 36 months.

Results were first posted in Oct 2025, 1 year after primary completion.

Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 36 months is above that.

Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2021
First posted
Aug 10, 2021
StartActual
Sep 27, 2021
Primary completionActual
Oct 16, 2024
CompletionActual
Dec 27, 2024
Results first posted
Oct 23, 2025
Last update
Oct 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04998604
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Aug 10, 2021
Start date
Sep 27, 2021
Primary completion
Oct 16, 2024
Completion
Dec 27, 2024
Results posted
Oct 23, 2025
Last update
Oct 23, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dupilumab · Omalizumab

Start the discussion